Nucleai
Andrew Harrison serves as the CEO and General Partner at Section 32. Previous roles include Executive Leadership at X (GoogleX) and Global Head of Business & Corporate Development at Verily (Google Life Sciences). Andrew has also held positions as Managing Director and Chief Operating Officer at Lapis Advisers, LP, and as Managing Director and Head of Partnerships at Fintan Partners, which was acquired by Cantor Fitzgerald. Additionally, Andrew was Vice President and Portfolio Manager at Northwater Capital Inc prior to its acquisition by Crestline Investors, Inc. Educational qualifications include a Master of Engineering in Chemical and Biomolecular Engineering from Cornell University and a Bachelor of Engineering in Chemical and Biomolecular Engineering from McGill University.
This person is not in the org chart
This person is not in any offices
Nucleai
7 followers
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects.